Results 81 to 90 of about 6,174 (184)

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. [PDF]

, 2019
PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the ...
Bosserman, Linda, Bryce, Richard, Di Palma, Jack A, Moran, Susan, Olek, Elizabeth, Rugo, Hope S, Tripathy, Debu   +6 more
core  

Immune Checkpoint Inhibitors vs. Targeted Therapy in BRAF‐Mutated Melanoma: A Systematic Review

Dermatologic Therapy, Volume 2026, Issue 1, 2026.
Background Skin cancer is a common malignancy. Although melanoma represents only 3% of cases, it causes 65% skin cancer–related deaths, with incidence rising worldwide. Melanoma’s severity stems from alterations in the MAPK pathway, triggered by BRAF mutations in 50% of melanoma cases.
Madeline Guy, Omar El-Kholy, Ahmed Adham R. Elsayed, Marc D. Basson, Nicola Pimpinelli   +4 more
wiley   +1 more source

Integrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers

Advanced Science, Volume 12, Issue 46, December 11, 2025.
Inspired by evidence triangulation, a new sensitivity method called MR‐DEG is developed, which uses the differentially expressed gene (DEG) results as additional evidence to minimize pleiotropic effects and strengthen Mendelian randomization (MR) causal estimates. Using dynamic single‐cell expression quantitative trait loci (eQTLs) as an example, it is
Jie Zheng, Qian Yang, Haoyu Liu, Huiling Zhao, Shuangyuan Wang, Yi Liu, Xueyan Wu, Yilan Ding, Hui Ying, Youqiu Ye, Xi Huang, Lei Ye, Ruizhi Zheng, Hong Lin, Mian Li, Tiange Wang, Zhiyun Zhao, Min Xu, Yi Duan, Hao Guo, Zhongshang Yuan, Philip Haycock, George Davey Smith, Richard M Martin, Guang Ning, Fang Hu, Weiqing Wang, Tom R. Gaunt, Jieli Lu, Yufang Bi   +29 more
wiley   +1 more source

Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Purpose A significant proportion of patients with locoregional (stage III) cutaneous melanoma recur despite adjuvant systemic therapy. Staging criteria and surgical nodal management have changed since the trials were completed. Data assessing the effect of systemic therapy compared to surveillance are limited, and factors associated with ...
Derek Effiom, Tyler Aprati, Anastasios Karneris, Aleigha Lawless, Tatyana Sharova, Rebecca Johnson, Alexander Menzies, Georgina Long, Benjamin Park, Seungyeon Jung, Douglas Johnson, David Liu, Xue Bai, Keith Flaherty, Ryan Sullivan, Genevieve M. Boland, Sonia Cohen   +16 more
wiley   +1 more source

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆

ESMO Real World Data and Digital Oncology
Background: Understanding of comparative efficacy of treatments can inform clinical decision-making. This study compared overall survival (OS) and progression-free survival (PFS) across patients with metastatic BRAFV600-mutant melanoma initiating ...
G.K. In, K. Chen, G. Sajeev, R. Simpson, S. Kalia, D. Christensen, D. Liu, N. Rezai, A. di Pietro, J. Signorovitch   +9 more
doaj   +1 more source

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase

Acta Dermato-Venereologica, 2020
The approval of BRAF and MEK inhibitors has significantly improved treatment outcomes for patients with BRAF-mutated metastatic melanoma. The 3 first-line targeted therapy trials have provided similar results, and thus the identification of predictive ...
Valerie Glutsch, Teresa Amaral, Claus Garbe, Kai-Martin Thoms, Peter Mohr, Axel Hauschild, Bastian Schilling   +6 more
doaj   +1 more source

Therapeutic Management of Patients with Metastatic BRAF-Mutated Melanoma: A Case Series Encompassing Different Clinical Scenarios

Onco
In the context of advanced BRAF-mutant melanoma, the treatment landscape has undergone a paradigm shift due to the impact of immune checkpoint inhibitors and BRAF/MEK inhibitors.
Ana Arance, Roberto Díaz, Eva Muñoz-Couselo, Teresa Puértolas, Almudena García Castaño, Rafael López Castro, Gretel Benítez López, Rubén de Toro, María Quindós, Enrique Espinosa, Pablo Ayala de Miguel, Margarita Majem   +11 more
doaj   +1 more source

A Model Based Approach for Translation in Oncology - From Xenografts to RECIST [PDF]

, 2022
A major problem in drug development is translating results from preclinical studies to the clinical setting. Therefore, we evalu ate the translational potential of semi mechanistic tumor models (based on xenograft data) to predict clinical oncology ...
Baaz, Marcus, Cardilin, Tim, Jirstrand, Mats, Lignet, Floriane   +3 more
core  

Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report

Case Reports in Dermatology
Introduction: The development of new and changing melanocytic lesions has been increasingly reported as an adverse dermatologic toxicity of BRAF inhibitor therapy.
Karen Lam, Gregory A. Gates, Daniel Q. Bach, Kyle Cheng   +3 more
doaj   +1 more source

Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases

CA: A Cancer Journal for Clinicians, Volume 76, Issue 2, March/April 2026.
David Gritsch, Riley M. Fadden, Maura K. Mahar, Melin J. Khandsekar, Kevin S. Oh, Daniel P. Cahil III, Gavin P. Dunn, Ryan J. Sullivan, Priscilla K. Brastianos   +8 more
wiley   +1 more source